8-K: Corcept Therapeutics Q1 2026 Financial Results

Corcept Therapeutics reported Q1 2026 revenue of $164.9 million and raised its full-year revenue guidance to $950-$1,050 million following the FDA approval of Lifyorli.

Summary

• Reported Q1 2026 revenue of $164.9 million, an increase from $157.2 million in Q1 2025.
• Recorded a net loss of $31.8 million for the quarter, compared to a net income of $20.5 million in the prior year period.
• Increased full-year 2026 revenue guidance to a range of $950 million to $1,050 million.
• Maintained a strong cash and investment position of $515.4 million as of March 31, 2026.
• Operating expenses rose to $214.5 million, driven by the launch preparation for Lifyorli and growth initiatives for the Cushing's syndrome business.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report, as the company successfully navigated a major FDA approval and provided an optimistic outlook for profitability and revenue growth.

Positives

• FDA approval of Lifyorli (relacorilant) for platinum-resistant ovarian cancer achieved ahead of the PDUFA date.
• Increased 2026 revenue guidance reflects management confidence in product uptake.
• Lifyorli added to NCCN Guidelines as a preferred regimen for ovarian cancer.
• Strong cash position of $515.4 million provides runway for ongoing clinical development.
• Management expects a return to profitability in the second quarter of 2026.

Negatives

• Reported a net loss of $31.8 million in Q1 2026 compared to a profit in the same period last year.
• Operating expenses increased significantly by approximately 40% year-over-year.
• Diluted net loss per share was $0.30, a reversal from the $0.17 income per share in Q1 2025.

Risks

• Ongoing regulatory uncertainty regarding the New Drug Application (NDA) for relacorilant in Cushing's syndrome.
• Execution risk associated with the commercial launch of Lifyorli.
• Clinical trial outcomes for pipeline candidates (BELLA, MONARCH, DAZALS) remain uncertain.
• Potential for future operating losses if commercial uptake of new products does not meet expectations.

Future Outlook

Management expects to return to profitability in Q2 2026 and anticipates European Medicines Agency approval for relacorilant plus nab-paclitaxel by the end of the year. The company is also preparing for multiple clinical trial readouts, including the BELLA and MONARCH trials, and the initiation of a Phase 3 trial for dazucorilant in ALS.

Management Comments

• We have increased our 2026 revenue guidance to $950 $1,050 million.
• Corcept expects to return to profitability in the second quarter of 2026.
• We are engaged with the FDA to determine the best path forward for our New Drug Application (NDA) for relacorilant in Cushing's syndrome and are confident that the ultimate outcome will be approval.

Industry Context

StockSavvy.ai notes that Corcept is successfully transitioning from a single-product company to a diversified commercial-stage biotech. The aggressive investment in SG&A reflects a common industry trend where companies front-load expenses to capture market share immediately following FDA approvals.

Comparison to Industry Standards

• The 35% reduction in risk of death in the ROSELLA trial is a strong clinical benchmark for platinum-resistant ovarian cancer treatments.
• The company's focus on cortisol modulation remains a niche but high-barrier-to-entry segment compared to broader oncology competitors.
• The transition to a new pharmacy vendor for Cushing's syndrome is a standard operational move to optimize distribution efficiency.

Stakeholder Impact

• Shareholders may benefit from the increased revenue guidance and potential return to profitability.
• Patients with platinum-resistant ovarian cancer gain access to a new FDA-approved treatment option.
• Employees are focused on the commercial launch of Lifyorli and ongoing clinical trial execution.

Next Steps

• Release results from the BELLA trial by the end of 2026.
• Release results from the MONARCH trial by the end of 2026.
• Initiate Phase 3 trial of dazucorilant in ALS patients later in 2026.
• Await European Medicines Agency approval for relacorilant plus nab-paclitaxel.

Key Dates

Recommendation

The combination of a successful FDA approval, increased revenue guidance, and a clear path back to profitability makes this a compelling growth story for investors, despite the temporary dip into net loss due to launch-related expenses.

Keywords

Corcept Therapeutics, CORT, Lifyorli, relacorilant, Cushing's syndrome, ovarian cancer, biotech, cortisol modulation